Yahoo Web Search

Search results

1. www.biopharmadive.com › news › lilly-acquireLilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com › news › lilly-acquire

   • Cached

   Jun 29, 2023 · Eli Lilly has reached a deal to acquire Emergence Therapeutics, a German biotechnology startup focused on antibody-drug conjugates, or ADCs, the company confirmed to BioPharma Dive on Thursday.

2. www.life-sciences-europe.com › index-termEmergence Therapeutics–Lilly: investment, 202306 acquisition ...

   www.life-sciences-europe.com › index-term

   • Cached

   Jun 29, 2023 · The proprietary technology platform is being applied to develop the Company’s own therapeutic ATACs as well as in third-party collaborations. The lead candidate HDP-101 is a BCMA ATAC in clinical development for multiple myeloma.

   • Group: Eli Lilly (Group)
   • Money taker: Emergence Therapeutics AG

   • Money source: Eli Lilly & Co. Inc. (NYSE: LLY)
   • Period: 2023-06-29

3. heidelberg-pharma.com › images › filesAd hoc announcement - Heidelberg Pharma

   heidelberg-pharma.com › images › files

   Jun 29, 2023 · Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics. US pharma company Eli Lilly and Company acquires all shares of ADC developer Emergence Therapeutics. Heidelberg Pharma is one of the founding investors and will receive about USD 7 million after closing.

4. www.prnewswire.com › news-releases › emergenceEmergence Therapeutics Licenses Synaffix ADC Technology ...

   www.prnewswire.com › news-releases › emergence

   • Cached

   Sep 6, 2022 · Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to $360 million, plus royalties on commercial sales...

5. www.distilnfo.com › lifesciences › 2023/07/03Lilly to Buy European ADC Player Emergence Therapeutics

   www.distilnfo.com › lifesciences › 2023/07/03

   • Cached

   Jul 3, 2023 · Eli Lilly has acquired European startup Emergence Therapeutics, a biotech focused on developing antibody-drug conjugates (ADCs) for cancers with high unmet need. The most advanced candidate in Emergence’s pipeline is ETx-22, an ADC targeting Nectin-4, a protein found on malignant cells.

6. www.globenewswire.com › news-release › 2021/12/07Emergence Therapeutics raises €87 million Series A

   www.globenewswire.com › news-release › 2021/12/07

   • Cached

   Dec 7, 2021 · Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an...

7. People also ask

   Is Eli Lilly acquiring emergence Therapeutics?

   • Eli Lilly has reached a deal to acquire Emergence Therapeutics, a German biotechnology startup focused on antibody-drug conjugates, or ADCs, the company confirmed to BioPharma Dive on Thursday. In a short statement, European cancer drug developer and founding Emergence investor Heidelberg Pharma said Lilly is acquiring all of the startup’s shares.

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

   Where is emergence therapeutics based?

   • Emergence Therapeutics AG is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information, please visit: Synaffix' proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies.

   Emergence Therapeutics Licenses Synaffix ADC Technology Platform in …

   www.prnewswire.com/news-releases/emergence-therapeutics-licenses-synaffix-adc-technology-platform-in-360m-deal-301617866.html

   See all results for this question

   Where is emergent based?

   • Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need. Emergence is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information, please visit:

   Emergence Therapeutics raises €87 million Series A - GlobeNewswire

   www.globenewswire.com/news-release/2021/12/07/2347055/0/en/Emergence-Therapeutics-raises-87-million-Series-A-financing-to-advance-Nectin-4-ADC.html

   See all results for this question

   Why did emergence Therapeutics invest in an oversubscribed ADC round?

   • Proceeds from the financing will also support the development of a pipeline of further ADC candidates. Jack Elands, CEO of Emergence Therapeutics, commented: “The completion of this significantly oversubscribed round enables Emergence to execute on its strategy to become a dominant ADC developer.

   Emergence Therapeutics raises €87 million Series A - GlobeNewswire

   www.globenewswire.com/news-release/2021/12/07/2347055/0/en/Emergence-Therapeutics-raises-87-million-Series-A-financing-to-advance-Nectin-4-ADC.html

   See all results for this question

   Who owns emergence Therapeutics & sigilon Therapeutics?

   • The company on Thursday announced plans to acquire cell therapy developer Sigilon Therapeutics for up to $310 million, and previously announced a $2.4 billion deal to buy inflammatory disease drugmaker Dice Therapeutics. In addition to Heidelberg, Emergence is backed by Pontifax Venture Capital, RA Capital Management and OrbiMed.

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

   Will emergence Therapeutics raise €87 million Series A financing for nectin-4 ADC?

   • Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC Duisburg, Germany, 7 December 2021.

   Emergence Therapeutics raises €87 million Series A - GlobeNewswire

   www.globenewswire.com/news-release/2021/12/07/2347055/0/en/Emergence-Therapeutics-raises-87-million-Series-A-financing-to-advance-Nectin-4-ADC.html

   See all results for this question

8. www.life-sciences-europe.com › news › emergenceEmergence Therapeutics AG. (9/6/22). "Press Release ...

   www.life-sciences-europe.com › news › emergence

   • Cached

   Synaffix B.V. (Synaffix) and Emergence Therapeutics AG (“Emergence”) (“the Companies”) today announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix’s proprietary antibody drug conjugate (ADC) technologies comprising GlycoConnect ...